There were two novel small molecules approved in April 2022:
- mavacamten (Camzyos), an oral cardiac myosin inhibitor
- oteseconazole (Vivjoy), an oral antifungal (jump to section)
This deep dive explores each drug in more detail, including the industry context, the clinical data, the target rationale, mechanisms of action, and drug origins.
See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.
get free samples and a Premium trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: